Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Atezolizumab |
| Synonyms | |
| Therapy Description |
Tecentriq (atezolizumab) is a monoclonal antibody against PD-L1 (CD274), preventing activation of its receptor, potentially enhancing T-cell-mediated immune response to neoplasms and inhibiting T-cell inactivation (PMID: 29449897). Tecentriq (atezolizumab) is FDA approved for use in PD-L1 positive (IC >/= 5%) advanced or metastatic urothelial carcinoma not eligible for cisplatin-containing chemotherapy, in advanced or metastatic urothelial carcinoma not eligible for chemotherapy, in metastatic non-small cell lung cancer (NSCLC) progressed on platinum-containing therapy, as first-line therapy in metastatic NSCLC with high PD-L1 expression (TC>/=50% or IC>/=10%) and without EGFR or ALK alterations, for adjuvant treatment in patients with PD-L1-positive (>=1% tumor cell expression) NSCLC, in combination with bevacizumab, paclitaxel, and carboplatin as first-line therapy for non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound and carboplatin in metastatic non-squamous NSCLC with no EGFR or ALK aberrations, in combination with carboplatin and etoposide in extensive-stage small cell lung cancer, in combination with bevacizumab in hepatocellular carcinoma without prior systemic therapy, in combination with Cotellic (cobimetinib) and Zelboraf (vemurafenib) in unresectable or metastatic BRAF V600-mutated melanoma, and in pediatric and adult patients with unresectable or metastatic alveolar soft part sarcoma (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Atezolizumab | Tecentriq | RG7446|MPDL3280A | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | Tecentriq (atezolizumab) is a monoclonal antibody against PD-L1 (CD274), preventing activation of its receptor, potentially enhancing T-cell-mediated immune response to neoplasms and inhibiting T-cell inactivation (PMID: 29449897). Tecentriq (atezolizumab) is FDA approved for use in PD-L1 positive (IC >/= 5%) advanced or metastatic urothelial carcinoma not eligible for cisplatin-containing chemotherapy, in advanced or metastatic urothelial carcinoma not eligible for chemotherapy, in metastatic non-small cell lung cancer (NSCLC) progressed on platinum-containing therapy, as first-line therapy in metastatic NSCLC with high PD-L1 expression (TC>/=50% or IC>/=10%) and without EGFR or ALK alterations, for adjuvant treatment in patients with PD-L1-positive (>=1% tumor cell expression) NSCLC, in combination with bevacizumab, paclitaxel, and carboplatin as first-line therapy for non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound and carboplatin in metastatic non-squamous NSCLC with no EGFR or ALK aberrations, in combination with carboplatin and etoposide in extensive-stage small cell lung cancer, in combination with bevacizumab in hepatocellular carcinoma without prior systemic therapy, in combination with Cotellic (cobimetinib) and Zelboraf (vemurafenib) in unresectable or metastatic BRAF V600-mutated melanoma, and in pediatric and adult patients with unresectable or metastatic alveolar soft part sarcoma (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| MLH1 negative | endometrial cancer | sensitive | Atezolizumab | Guideline | Actionable | Immune checkpoint inhibitor monotherapy including Tecentriq (atezolizumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org). | detail... 36696825 |
| FGFR3 mutant | transitional cell carcinoma | no benefit | Atezolizumab | Phase II | Actionable | In a Phase II trial (IMVigor 210, CheckMate 275), Tecentriq (atezolizumab) (n=119) treatment resulted in similar response rate (24% vs 21%, p=0.8) in patients with FGFR3 mutant or wild-type metastatic transitional cell carcinoma (PMID: 31272788). | 31272788 |
| BRAF V600E | lung non-small cell carcinoma | not predictive | Atezolizumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, non-small cell lung cancer patients harboring BRAF V600E did not demonstrate a significantly different response to treatment with either Keytruda (pembrolizumab), Opdivo (nivolumab), or Tecentriq (atezolizumab) compared to patients with BRAF non-V600E mutations, demonstrating an objective response rate of 25% (3/12) vs 33% (3/9) (p=1.0) and median progression-free survival of 3.7 months vs 4.1 months (p=0.37) (PMID: 29723688). | 29723688 |
| ALK rearrange | lung non-small cell carcinoma | no benefit | Atezolizumab | Guideline | Actionable | Immune checkpoint inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), Tecentriq (atezolizumab), and Imfinzi (durvalumab) are not indicated for use as subsequent therapy in non-small cell lung cancer patients with ALK rearrangement (NCCN.org). | detail... |
| ALK rearrange | lung non-small cell carcinoma | no benefit | Atezolizumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694). | 27225694 |
| MSH6 negative | endometrial cancer | sensitive | Atezolizumab | Guideline | Actionable | Immune checkpoint inhibitor monotherapy including Tecentriq (atezolizumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org). | detail... 36696825 |
| PBRM1 inact mut | clear cell renal cell carcinoma | sensitive | Atezolizumab | Clinical Study - Cohort | Actionable | In a clinical study, renal clear cell carcinoma patients harboring PBRM1 loss-of-function mutations demonstrated improved response to immune checkpoint therapies including Opdivo (nivolumab) alone or in combination with Yervoy (ipilimumab), and Tecentriq (atezolizumab), potentially due to the distinct expression profile of immune-related genes in these patients (PMID: 29301960). | 29301960 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03708224 | Phase II | Atezolizumab + Emactuzumab Atezolizumab | Phase II Study of Perioperative Immunotherapy in Patients With Advanced Non-Virally Associated Squamous Cell Carcinoma | Recruiting | USA | 0 |
| NCT02708680 | Phase Ib/II | Atezolizumab Atezolizumab + Entinostat | Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In | Completed | USA | 1 |
| NCT02927301 | Phase II | Atezolizumab | A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Stage IB, II, or IIIA Resectable and Untreated Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | 0 |
| NCT02400814 | Phase I | Atezolizumab | MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer | Terminated | USA | 0 |
| NCT03474094 | Phase II | Atezolizumab | Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy (RT-Immune) | Recruiting | GBR | FRA | 0 |
| NCT03197935 | Phase III | Pegfilgrastim Doxorubicin Atezolizumab Filgrastim Nab-paclitaxel Cyclophosphamide | A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer (IMpassion031) | Completed | USA | POL | ITA | GBR | ESP | DEU | CAN | BRA | BEL | AUS | 3 |
| NCT02350673 | Phase I | Cergutuzumab amunaleukin Atezolizumab | A Study of Intravenous RO6895882 and MPDL3280A Combination in Patients With Locally Advanced and/or Metastatic Solid Tumors | Completed | USA | NLD | ESP | DNK | CHE | CAN | 0 |
| NCT05770102 | Phase II | Atezolizumab | DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition (DETERMINE) | Recruiting | GBR | 0 |
| NCT03120676 | Phase II | Atezolizumab | Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma | Terminated | USA | 0 |
| NCT03563716 | Phase II | Atezolizumab + Tiragolumab Atezolizumab | A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Active, not recruiting | USA | FRA | ESP | 3 |
| NCT04387084 | Phase I | Durvalumab Pembrolizumab Avelumab Cemiplimab Atezolizumab Nivolumab | Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy | Active, not recruiting | USA | 0 |
| NCT03029832 | Phase II | Atezolizumab Atezolizumab + Vonlerolizumab | A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy | Terminated | USA | GBR | CAN | BEL | 1 |
| NCT04334941 | Phase II | Atezolizumab + Talazoparib Atezolizumab | Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker | Active, not recruiting | USA | 0 |
| NCT03285763 | FDA approved | Atezolizumab | A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (TAIL) | Completed | SWE | SVN | POL | NLD | LVA | LBN | ITA | GRC | GBR | ESP | DNK | BRA | ARG | 11 |
| NCT04817956 | Phase II | Ceritinib Melphalan Cobimetinib + Vemurafenib Alectinib Pemigatinib Entrectinib Bortezomib Dostarlimab-gxly Atezolizumab Alpelisib Atezolizumab + Bevacizumab Olaparib Selpercatinib Capmatinib Dactinomycin Dabrafenib + Trametinib Vismodegib Niraparib Imatinib Pertuzumab/trastuzumab/hyaluronidase-zzxf | Improving Public Cancer Care by Implementing Precision Medicine in Norway (IMPRESS-N) | Recruiting | NOR | 0 |
| NCT04770272 | Phase II | Atezolizumab + Carboplatin + Paclitaxel Atezolizumab + Cyclophosphamide + Epirubicin Atezolizumab | Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy (neoMono) | Completed | DEU | 0 |
| NCT06069726 | Phase II | Atezolizumab | A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial (MOAB) | Recruiting | USA | 0 |
| NCT03979066 | Phase II | Atezolizumab Atezolizumab + PEGPH20 | Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma (NEOiPANC) | Terminated | USA | 0 |
| NCT02409342 | Phase III | Atezolizumab Carboplatin Pemetrexed Disodium Cisplatin | A Comparative Study of MPDL3280A (Anti-PDL1 Antibody) With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | TUR | ROU | POL | ITA | HUN | GRC | GBR | FRA | ESP | DEU | BRA | 7 |
| NCT02431208 | Phase I | Lenalidomide Atezolizumab | A Study of Atezolizumab (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) Administered With or Without Lenalidomide in Participants With Multiple Myeloma (MM) | Completed | USA | 0 |
| NCT04300647 | Phase II | Atezolizumab Atezolizumab + Tiragolumab | A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer (SKYSCRAPER-04) | Active, not recruiting | USA | POL | ITA | GBR | FRA | ESP | CAN | BRA | AUS | 8 |
| NCT04272645 | Phase II | Abemaciclib + Atezolizumab Abemaciclib Atezolizumab | Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer | Withdrawn | USA | 0 |
| NCT02792192 | Phase Ib/II | Atezolizumab + BCG solution Atezolizumab | Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-risk Non-muscle-invasive Bladder Cancer (NMIBC) Participants | Terminated | USA | 0 |
| NCT03614949 | Phase II | Atezolizumab | SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer | Recruiting | USA | 0 |
| NCT04214262 | Phase III | Atezolizumab | Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
| NCT05333458 | Phase II | Atezolizumab + Selinexor Atezolizumab | Testing Atezolizumab With or Without Selinexor in Patients >= 18 Years Old With Alveolar Soft Part Sarcoma | Recruiting | USA | 0 |
| NCT05060003 | Phase II | Atezolizumab Atezolizumab + Tiragolumab | Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection | Terminated | USA | 0 |
| NCT04221529 | Phase II | Atezolizumab | Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide (SPACE) | Active, not recruiting | DEU | AUT | 0 |
| NCT03024437 | Phase Ib/II | Atezolizumab + Entinostat Atezolizumab + Bevacizumab + Entinostat Atezolizumab | Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma | Suspended | USA | 0 |
| NCT05053737 | Phase Ib/II | Atezolizumab | Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC | Suspended | USA | 0 |
| NCT04660344 | Phase III | Atezolizumab | A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy (IMvigor011) | Active, not recruiting | USA | TUR | POL | ITA | ISR | IRL | GRC | GBR | FRA | ESP | DEU | CZE | BRA | BEL | ARG | 9 |
| NCT02367794 | Phase III | Carboplatin Nab-paclitaxel Paclitaxel Atezolizumab | A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | SVK | NLD | LVA | LTU | ITA | ISR | FRA | ESP | DEU | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 9 |
| NCT04936230 | Phase II | Atezolizumab | Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer | Active, not recruiting | USA | 0 |
| NCT02108652 | Phase II | Atezolizumab | A Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer | Completed | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | 0 |
| NCT04157985 | Phase III | Nivolumab Ipilimumab Pembrolizumab Atezolizumab | Evaluation of the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT04341181 | Phase II | Atezolizumab Niraparib Erlotinib Axitinib Cobimetinib + Vemurafenib Avelumab Pertuzumab + Trastuzumab Vismodegib Alectinib Ado-trastuzumab emtansine | ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling (ProTarget) | Recruiting | DNK | 0 |
| NCT03201458 | Phase II | Atezolizumab Atezolizumab + Cobimetinib | Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery | Completed | USA | 0 |
| NCT02410512 | Phase I | Vonlerolizumab Atezolizumab | A Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and MPDL3280A in Patients With Locally Advanced or Metastatic Solid Tumors | Completed | USA | FRA | ESP | CAN | BEL | AUS | 1 |
| NCT04185831 | Phase II | Atezolizumab Niraparib Cobimetinib Everolimus | A MolEcularly Guided Anti-Cancer Drug Off-Label Trial (MEGALiT) | Active, not recruiting | SWE | 0 |
| NCT02463994 | Phase I | Atezolizumab | A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC | Completed | USA | 0 |
| NCT02992912 | Phase II | Atezolizumab | Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours (SABR-PDL1) | Active, not recruiting | FRA | 0 |
| NCT05180006 | Phase II | Atezolizumab Atezolizumab + Pertuzumab + Trastuzumab Atezolizumab + Ipatasertib Atezolizumab + Bevacizumab | Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy (BIS-Program) | Recruiting | FRA | 0 |
| NCT06267001 | Phase III | Atezolizumab Atezolizumab + Tiragolumab | A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy (SKYSCRAPER-15) | Active, not recruiting | USA | TUR | SVK | POL | ITA | FRA | ESP | BRA | AUS | ARG | 6 |
| NCT05344209 | Phase II | Atezolizumab Pembrolizumab Cemiplimab Cemiplimab + Sargramostim + UV1 Telomerase peptide vaccine Pembrolizumab + Sargramostim + UV1 Telomerase peptide vaccine Atezolizumab + Sargramostim + UV1 Telomerase peptide vaccine | Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer (LUNGVAC) | Recruiting | NOR | 0 |
| NCT03483012 | Phase II | Atezolizumab | Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis | Active, not recruiting | USA | 0 |
| NCT02367781 | Phase III | Atezolizumab Carboplatin + Nab-paclitaxel | A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel in Patients With Non-Squamous Non-Small Cell Lung Cancer | Completed | USA | ITA | ISR | FRA | ESP | DEU | CAN | BEL | 0 |
| NCT03024996 | Phase III | Atezolizumab | A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010) | Terminated | USA | TUR | POL | NLD | ITA | ISR | IRL | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 9 |
| NCT05470595 | Phase II | Atezolizumab | A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung (LCNEC-ALPINE) | Recruiting | DEU | 0 |
| NCT04462276 | Phase II | Atezolizumab | Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease (TREASURE) | Active, not recruiting | DEU | AUT | 0 |
| NCT01903993 | Phase II | Atezolizumab | A Randomized Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR" | Completed | USA | TUR | SWE | POL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | 2 |
| NCT04591431 | Phase II | Everolimus Nivolumab Itacitinib Erlotinib Ponatinib Pemigatinib Ipatasertib Ipilimumab Cobimetinib Atezolizumab Palbociclib Entrectinib Vemurafenib Lapatinib Trastuzumab Brigatinib Alectinib Ado-trastuzumab emtansine Pertuzumab Vismodegib | The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (ROME) | Active, not recruiting | ITA | 0 |
| NCT03896074 | Phase II | Atezolizumab + Bevacizumab Atezolizumab | Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT) (BEAT) | Unknown status | ITA | 0 |
| NCT04302025 | Phase II | Cobimetinib + Vemurafenib Entrectinib Atezolizumab Alectinib Pralsetinib | A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
| NCT04267237 | Phase II | Atezolizumab + Autogene cevumeran Atezolizumab | A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer | Withdrawn | 0 | |
| NCT02599454 | Phase I | Atezolizumab | Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
| NCT04996017 | Phase III | Atezolizumab | Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso) (AtezoMeso) | Unknown status | ITA | 0 |
| NCT04710498 | Phase II | Atezolizumab | Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
| NCT04477759 | Phase I | Atezolizumab | Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer (DEHART) | Active, not recruiting | USA | 0 |
| NCT04610684 | Phase II | Atezolizumab Atezolizumab + Carboplatin + Etoposide | Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases | Terminated | USA | 0 |
| NCT04637594 | Phase III | Durvalumab Nivolumab Atezolizumab Avelumab Pembrolizumab | Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy | Active, not recruiting | USA | 0 |
| NCT03452137 | Phase III | Atezolizumab | A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck | Terminated | USA | TUR | POL | ITA | HUN | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | 10 |
| NCT02589717 | FDA approved | Atezolizumab | An Expanded Access Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy | Approved for marketing | USA | 0 |
| NCT02409355 | Phase III | Carboplatin Cisplatin Gemcitabine Atezolizumab | A Study of MPDL3280A Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer | Terminated | USA | ROU | POL | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CZE | 3 |
| NCT02541604 | Phase I | Atezolizumab | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MPDL3280A (Anti-PD-L1 Antibody) in Pediatric and Young Adult Participants With Solid Tumors | Terminated | USA | NLD | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CHE | CAN | 0 |
| NCT02451423 | Phase II | Atezolizumab | Study of MPDL3280A in Bladder Cancer | Completed | USA | 0 |
| NCT03191786 | Phase III | Atezolizumab Gemcitabine Vinorelbine | A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy (IPSOS) | Completed | SVK | ROU | POL | LUX | ITA | IRL | GBR | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BGR | BEL | ARG | 7 |
| NCT02525757 | Phase II | Atezolizumab Carboplatin + Paclitaxel | MPDL3280A With Chemoradiation for Lung Cancer | Active, not recruiting | USA | 0 |
| NCT04017455 | Phase II | Bevacizumab Atezolizumab Atezolizumab + Bevacizumab | Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN) (TARZAN) | Unknown status | NLD | 0 |
| NCT05459129 | Phase Ib/II | Atezolizumab Atezolizumab + Carboplatin + Paclitaxel + Tiragolumab Atezolizumab + Tiragolumab | A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer) | Completed | USA | ISR | FRA | AUS | 1 |
| NCT05038657 | Phase II | Atezolizumab | Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC). (AURORA) | Recruiting | GBR | 0 |
| NCT03023423 | Phase Ib/II | Atezolizumab + Daratumumab Atezolizumab | A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (DARZALEX) | Completed | USA | POL | HUN | FRA | ESP | 0 |
| NCT05118724 | Phase II | Atezolizumab | Atezolizumab in Patients With MSI-h/MMR-D Stage III Colorectal Cancer Ineligible for Oxaliplatin (ANTONIO) | Recruiting | DEU | 0 |
| NCT03178851 | Phase I | Atezolizumab Atezolizumab + Cobimetinib | Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma | Completed | USA | ESP | BRA | AUS | 3 |
| NCT02508870 | Phase I | Azacitidine Atezolizumab | A Safety and Pharmacology Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes | Completed | USA | 0 |
| NCT03697850 | Phase II | Atezolizumab | Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy (BladderSpar) | Active, not recruiting | FRA | 0 |
| NCT04563338 | Phase II | Atezolizumab Atezolizumab + Bevacizumab | An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE) | Recruiting | CAN | 0 |
| NCT03821246 | Phase II | Atezolizumab + Emactuzumab Atezolizumab Atezolizumab + Enzalutamide | Neoadjuvant Atezolizumab With or Without Enzalutamide in Localized Prostate Cancer Given Before Radical Prostatectomy | Recruiting | USA | 0 |
| NCT03473756 | Phase Ib/II | Atezolizumab Atezolizumab + Rogaratinib | Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma (FORT-2) | Completed | USA | ITA | FRA | ESP | DEU | AUT | 2 |
| NCT02314481 | Phase II | Vemurafenib Atezolizumab Alectinib Ado-trastuzumab emtansine | Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (DARWINII) | Active, not recruiting | GBR | 0 |
| NCT03498521 | Phase II | Atezolizumab + Paclitaxel Carboplatin Carboplatin + Paclitaxel Olaparib Vismodegib Alectinib Bevacizumab + Erlotinib Cisplatin + Gemcitabine Cobimetinib + Vemurafenib Ipatasertib + Paclitaxel Cisplatin + Paclitaxel Gemcitabine Atezolizumab Entrectinib Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab Ipatasertib Carboplatin + Gemcitabine | A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site (CUPISCO) | Active, not recruiting | TUR | ROU | POL | NOR | NLD | LVA | ITA | ISR | IRL | HUN | HRV | GRC | GBR | FRA | FIN | EST | ESP | DNK | DEU | CZE | CHE | BRA | BGR | AUT | AUS | 8 |
| NCT03158389 | Phase Ib/II | Vismodegib Alectinib Idasanutlin Temsirolimus Atezolizumab Palbociclib APG101 | NCT Neuro Master Match - N²M² (NOA-20) (N²M²) | Completed | DEU | 0 |
| NCT05159245 | Phase II | Vemurafenib Tepotinib Vismodegib Apalutamide Alectinib Regorafenib Entrectinib Pertuzumab + Trastuzumab Pemigatinib Atezolizumab Cobimetinib Dabrafenib + Trametinib Dabrafenib Trametinib Abemaciclib | The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs (FINPROVE) | Recruiting | FIN | 0 |
| NCT02091141 | Phase II | Erlotinib Alectinib Cobimetinib + Vemurafenib Pertuzumab + Trastuzumab Vismodegib Atezolizumab | My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors | Completed | USA | 0 |
| NCT04294810 | Phase III | Atezolizumab Atezolizumab + Tiragolumab | A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (SKYSCRAPER-01) | Active, not recruiting | USA | TUR | POL | NLD | ITA | HUN | GRC | ESP | DNK | DEU | CHE | BRA | AUT | AUS | 10 |
| NCT04273061 | Phase II | Atezolizumab | Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity (CAPTIV-8) | Recruiting | CAN | 0 |
| NCT03767075 | Phase II | Amivantamab-vmjw Futibatinib Atezolizumab | A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) (BoB) | Recruiting | SWE | NLD | ITA | GBR | FRA | ESP | DEU | 0 |
| NCT02994576 | Phase II | Atezolizumab | Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer (PRINCEPS) | Completed | FRA | 0 |
| NCT02784483 | Phase I | Atezolizumab | Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma | Terminated | USA | 0 |
| NCT04624399 | Phase II | Atezolizumab | Phase 2 Study of Neoadjuvant Immune Checkpoint Inhibitors in Urothelial Cancer (ABACUS-2) | Recruiting | GBR | 0 |
| NCT03513952 | Phase II | Atezolizumab + CYT107 Atezolizumab | Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma | Completed | USA | 0 |
| NCT03237780 | Phase II | Atezolizumab Atezolizumab + Eribulin | Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer | Active, not recruiting | USA | 0 |
| NCT02928406 | Phase III | Atezolizumab | A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract | Completed | SVK | ROU | POL | NLD | LTU | LBN | ITA | IRL | HUN | HRV | GRC | GBR | EST | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 7 |
| NCT04751929 | Phase II | Abemaciclib + Atezolizumab Atezolizumab Abemaciclib | Abemaciclib With or Without Atezolizumab for mCRPC | Active, not recruiting | USA | 0 |
| NCT02008227 | Phase III | Docetaxel Atezolizumab | A Randomized Phase 3 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - OAK | Completed | USA | TUR | SWE | POL | NZL | NOR | NLD | ITA | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CHE | CAN | BRA | AUT | ARG | 11 |
| NCT03313804 | Phase II | Pembrolizumab Atezolizumab Nivolumab | Priming Immunotherapy in Advanced Disease With Radiation | Active, not recruiting | USA | 0 |
| NCT02302807 | Phase III | Paclitaxel Vinorelbine Atezolizumab Docetaxel | A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer | Completed | USA | TUR | SWE | SVN | ROU | POL | NOR | NLD | ITA | HUN | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BEL | AUT | AUS | 6 |
| NCT03768063 | FDA approved | Atezolizumab | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B) | Recruiting | USA | SVK | ROU | POL | NOR | LVA | ITA | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUS | 12 |
| NCT03464942 | Phase II | Atezolizumab | Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer (AZTEC) | Completed | AUS | 0 |
| NCT03620435 | Phase II | Atezolizumab | Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer | Unknown status | CAN | 0 |
| NCT05110781 | Phase II | Atezolizumab | Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site | Terminated | USA | 0 |
| NCT03281954 | Phase III | Atezolizumab | Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo | Active, not recruiting | USA | CAN | 0 |
| NCT02420821 | Phase III | Bevacizumab Sunitinib Atezolizumab | A Study of MPDL3280A (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma | Completed | USA | TUR | POL | ITA | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | AUS | 8 |
| NCT03148418 | Phase II | Atezolizumab | A Study in Participants Previously Enrolled in a Genentech? and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study | Active, not recruiting | USA | TUR | SVN | ROU | POL | NZL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 9 |
| NCT03102242 | Phase II | Atezolizumab | Atezolizumab Immunotherapy in Patients With Advanced NSCLC | Completed | USA | 0 |
| NCT04458922 | Phase II | Atezolizumab | Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma | Active, not recruiting | USA | CAN | 0 |
| NCT03735121 | Phase III | Atezolizumab + rHuPH20 Atezolizumab | A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Active, not recruiting | TUR | POL | NZL | LVA | ITA | HUN | GRC | GBR | FRA | ESP | BRA | ARG | 11 |
| NCT02304393 | Phase I | Selicrelumab Atezolizumab | A Study of RO7009789 in Combination With MPDL3280A in Patients With Locally Advanced and Metastatic Solid Tumors | Completed | USA | NLD | FRA | ESP | DNK | CAN | 0 |
| NCT02997228 | Phase III | Atezolizumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin | Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Microsatellite Instability-High Metastatic Colorectal Cancer | Recruiting | USA | 0 |
| NCT02848651 | Phase II | Atezolizumab | A Study of Atezolizumab (MPDL3280A) as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): Clinical Evaluation of Novel Blood-Based Diagnostics [B-F1RST] | Completed | USA | 0 |
| NCT05798663 | Phase II | Atezolizumab Atezolizumab + Tiragolumab | Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC | Recruiting | USA | 0 |
| NCT02862275 | Phase 0 | Atezolizumab | Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer | Active, not recruiting | USA | CAN | 0 |
| NCT03340558 | Phase II | Atezolizumab Atezolizumab + Cobimetinib | Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer (ATELIER) | Withdrawn | USA | 0 |
| NCT03178552 | Phase II | Entrectinib Carboplatin + Cisplatin + Gemcitabine Atezolizumab Carboplatin + Cisplatin + Pemetrexed Disodium Divarasib Atezolizumab + Cobimetinib + Vemurafenib Alectinib | A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST) | Active, not recruiting | USA | TUR | POL | NZL | ITA | ISR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | ARG | 14 |
| NCT03424005 | Phase Ib/II | Atezolizumab + Bevacizumab + Selicrelumab Atezolizumab + RO6874281 Atezolizumab + Bevacizumab Atezolizumab + Carboplatin + Gemcitabine Atezolizumab + Eribulin Capecitabine Atezolizumab Atezolizumab + Bevacizumab + Cobimetinib Atezolizumab + Capecitabine Atezolizumab + Ipatasertib Atezolizumab + Ladiratuzumab vedotin | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC) (Morpheus-TNBC) | Recruiting | USA | ISR | GBR | FRA | ESP | DEU | AUS | 1 |
| NCT03337698 | Phase Ib/II | Atezolizumab + Carboplatin + Gemcitabine Atezolizumab + CPI-444 Atezolizumab Atezolizumab + Docetaxel Docetaxel Atezolizumab + Cobimetinib Atezolizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + RO6958688 | A Study Evaluating ThA Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus Lung) | Active, not recruiting | USA | ISR | GBR | FRA | ESP | AUS | 2 |
| NCT05423210 | Phase I | Atezolizumab | Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme | Recruiting | USA | 0 |
| NCT02031458 | Phase II | Atezolizumab | A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - BIRCH | Completed | USA | TUR | SVN | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | BGR | BEL | AUS | 5 |
| NCT06492954 | Phase I | Atezolizumab | Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma (AflacST2301) | Recruiting | USA | 0 |
| NCT04020809 | Phase I | Atezolizumab | Neoadjuvant Atezolizumab in Cutaneous Melanoma | Active, not recruiting | USA | 0 |
| NCT03548428 | Phase II | Atezolizumab | Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc) (Stereosarc) | Recruiting | FRA | 0 |
| NCT05238831 | Phase II | Vemurafenib Vinorelbine Palbociclib Irinotecan Alpelisib Capecitabine Atezolizumab Paclitaxel Entrectinib Cobimetinib Nab-paclitaxel Fulvestrant Carboplatin Olaparib Pertuzumab/trastuzumab/hyaluronidase-zzxf Niraparib Vismodegib Alectinib Letrozole Ado-trastuzumab emtansine Bevacizumab Eribulin Anastrozole | SMMART Adaptive Clinical Treatment (ACT) Trial | Withdrawn | 0 | |
| NCT05703997 | Phase II | Atezolizumab | FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction (FASTIMMUNE) | Not yet recruiting | ITA | 0 |
| NCT03869190 | Phase Ib/II | Atezolizumab + Tocilizumab Atezolizumab + Niraparib Atezolizumab + Hu5F9-G4 Atezolizumab + Enfortumab vedotin-ejfv Atezolizumab + Linagliptin Atezolizumab + Isatuximab Atezolizumab | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy (MORPHEUS mUC) | Active, not recruiting | USA | GRC | GBR | FRA | ESP | 2 |
| NCT02486718 | Phase III | Atezolizumab | Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer | Active, not recruiting | USA | ROU | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 8 |
| NCT03014648 | Phase II | Atezolizumab | Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) | Completed | USA | 0 |
| NCT06096779 | Phase II | Atezolizumab + Bevacizumab Atezolizumab | A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis (Kirros) | Recruiting | USA | 1 |
| NCT01375842 | Phase I | Atezolizumab | A Phase 1 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors | Completed | USA | GBR | FRA | ESP | 0 |
| NCT04801966 | Phase 0 | Palbociclib Alpelisib Atezolizumab Vemurafenib Ribociclib Talazoparib Cobimetinib Trametinib Abemaciclib Dabrafenib Nivolumab Binimetinib Pembrolizumab Encorafenib | Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study (TAILOR) | Terminated | AUS | 0 |
| NCT04939480 | Phase II | Atezolizumab | Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN (PIONEER) | Completed | DEU | 0 |
| NCT05332561 | Phase II | Olaparib Ipatasertib Sacituzumab govitecan-hziy Inavolisib Pertuzumab/trastuzumab/hyaluronidase-zzxf Atezolizumab | Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE) | Recruiting | DEU | 0 |
| NCT03206047 | Phase Ib/II | Atezolizumab + Guadecitabine Atezolizumab Atezolizumab + Guadecitabine + Rasdegafusp alfa | Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Active, not recruiting | USA | 0 |
| NCT03465891 | Phase II | Atezolizumab | Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma | Terminated | USA | 0 |
| NCT02471846 | Phase I | Navoximod Atezolizumab | A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors | Completed | USA | FRA | ESP | 1 |
| NCT04322643 | Phase II | Durvalumab Pembrolizumab Avelumab Nivolumab Atezolizumab | Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma | Completed | USA | 0 |
| NCT04551521 | Phase II | Atezolizumab Atezolizumab + Ipatasertib Atezolizumab + Pertuzumab + Trastuzumab Atezolizumab + Cobimetinib Alectinib Atezolizumab + Cobimetinib + Vemurafenib | CRAFT: The NCT-PMO-1602 Phase II Trial | Recruiting | DEU | 0 |
| NCT04310020 | Phase II | Atezolizumab | Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients | Recruiting | USA | 0 |
| NCT05722886 | Phase II | Cobimetinib + Vemurafenib Alectinib Pertuzumab + Trastuzumab Entrectinib Atezolizumab | DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol (DETERMINE) | Recruiting | GBR | 0 |
| NCT02788279 | Phase III | Atezolizumab Atezolizumab + Cobimetinib Regorafenib | A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma | Completed | USA | POL | ITA | GBR | ESP | CAN | BEL | AUS | 3 |
| NCT03976518 | Phase II | Atezolizumab | Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial) (CHANCE) | Completed | ITA | 0 |
| NCT05836584 | Phase II | Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab Atezolizumab + Capecitabine + Oxaliplatin | Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer | Recruiting | USA | 0 |
| NCT02609984 | Phase II | Atezolizumab G305 + ID-LV305 | Trial of CMB305 and Atezolizumab in Patients With Sarcoma | Terminated | USA | 0 |
| NCT03141684 | Phase II | Atezolizumab | Atezolizumab in Treating Patients With Newly Diagnosed and Metastatic Alveolar Soft Part Sarcoma That Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
| NCT06416436 | Phase I | Atezolizumab | Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients | Not yet recruiting | USA | 0 |
| NCT02844816 | Phase II | Atezolizumab | Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer | Active, not recruiting | USA | CAN | 0 |
| NCT01984242 | Phase II | Atezolizumab Sunitinib Atezolizumab + Bevacizumab + Capecitabine | A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) as Monotherapy or in Combination With Avastin (Bevacizumab) Compared to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma | Completed | USA | ROU | POL | ITA | GBR | FRA | ESP | DEU | CZE | 0 |
| NCT04138628 | Phase II | Atezolizumab | Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy (TOMBOLA) | Recruiting | DNK | 0 |
| NCT05645692 | Phase II | Atezolizumab RO7247669 RO7247669 + Tiragolumab | A Study of RO7247669 Alone or in Combination With Tiragolumab vs Atezolizumab in Participants With Untreated Locally Advanced or Metastatic Urothelial Cancer | Active, not recruiting | USA | TUR | POL | ITA | GRC | GBR | FRA | ESP | DNK | DEU | BRA | AUS | 3 |
| NCT05334329 | Phase I | Cyclophosphamide + Fludarabine Atezolizumab TRACK-NK cells | Genetically Engineered Cells (COH06) With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors | Active, not recruiting | USA | 0 |
| NCT03115801 | Phase II | Atezolizumab Nivolumab | A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers | Terminated | USA | 0 |
| NCT02458638 | Phase II | Atezolizumab | An Open Label Study of MPDL3280A in Advanced Solid Tumors | Completed | USA | TUR | POL | NOR | NLD | ITA | IRL | GBR | FRA | FIN | ESP | DNK | DEU | CHE | CAN | BRA | AUT | 1 |
| NCT03056599 | Phase I | Pembrolizumab Avelumab Interferon gamma Olaratumab Trabectedin Nivolumab Gemcitabine Interferon alpha-2b Doxorubicin Atezolizumab Eribulin Ipilimumab Durvalumab Aldesleukin Bortezomib Docetaxel | Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma | Completed | USA | 0 |
| NCT05394337 | Phase I | Tiragolumab Atezolizumab | Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma | Recruiting | USA | 0 |
| NCT04665843 | Phase II | Atezolizumab + Tiragolumab Atezolizumab | A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck (SKYSCRAPER-09) | Active, not recruiting | USA | POL | NZL | ITA | HUN | GRC | GBR | FRA | ESP | CZE | 3 |
| NCT06331598 | Phase II | Atezolizumab Atezolizumab + Tiragolumab | A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) (IMperator) | Recruiting | ESP | 0 |
| NCT06254911 | Phase II | Atezolizumab | Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma | Recruiting | USA | 0 |
| NCT04402788 | Phase II | Atezolizumab Atezolizumab + Radiotherapy | Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial | Recruiting | USA | 0 |
| NCT05085496 | Phase I | Atezolizumab | Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous Squamous Cell Carcinoma | Recruiting | USA | 0 |
| NCT04186013 | Phase II | Atezolizumab | Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cancer | Active, not recruiting | ESP | 0 |
| NCT03467360 | Phase I | Atezolizumab | Inhibition of CArbonic Anhydrase in Combination With Platinum and Etoposide-based Radiochemotherapy in Patients With Localized Small Cell Lung Cancer (ICAR) | Recruiting | FRA | 0 |
| NCT04543617 | Phase III | Atezolizumab Atezolizumab + Tiragolumab | A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma (SKYSCRAPER-07) | Active, not recruiting | USA | TUR | POL | NZL | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CHE | BEL | AUT | AUS | ARG | 11 |
| NCT02450331 | Phase III | Atezolizumab | A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection (IMvigor010) | Terminated | USA | TUR | POL | NLD | ITA | ISR | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BEL | AUS | 7 |
| NCT03555149 | Phase Ib/II | Atezolizumab Atezolizumab + Isatuximab Atezolizumab + Bevacizumab + PGG beta-glucan | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) | Terminated | USA | FRA | CHE | AUS | 1 |
| NCT05171777 | Phase II | Atezolizumab | A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer | Active, not recruiting | USA | POL | LVA | ITA | FIN | ESP | CAN | BRA | ARG | 3 |
CKB BOOST